
Arjo came into this Q3 2026 report with its stock at SEK32.32 and a strong run over the past quarter, up 22.4% over 90 days. Expectations around a margin rebuild were high for a business that sells critical patient handling and mobility equipment into stretched healthcare systems.
The headline this quarter is clear. Revenue reached SEK2,849m while adjusted EBIT climbed to SEK247m with a 7.2% reported EBIT margin, helped by a tariff reimbursement and better product mix. If the share price reaction feels muted next to that improvement, the gap between a repaired income statement and lingering worries about debt and past profit pressure is what investors are really pricing.
Love the margin rebuild at Arjo but still concerned about leverage and past profit pressure sitting in the background of OM:ARJO B? Compare it with our list of solid balance sheet and fundamentals stocks (203 results) for businesses that pair earnings power with cleaner balance sheets.
Tired of scrolling through pages of Arjo figures and margin details? See the complete visual overview, including how valuation compares with the latest earnings story, in the company report for Arjo.
Optimists argue Arjo’s efficiency push can rebuild earnings quality without choking off growth in core care solutions.
"The main thing that has to go right is delivery of the SEK 350 million EBIT improvement programme through portfolio simplification, procurement efficiencies and more consistent commercial execution without undermining growth in beds, rental and long term care solutions."
Q3 shows early proof points. Organic growth of 6% came alongside higher gross margin and a 6.8% adjusted EBIT margin even after stripping out tariff and FX help. Cash conversion above 100% and net debt to adjusted EBITDA at 2.2x hint that Arjo is improving profitability while still funding beds and rental expansion.
The bear narrative questions whether Arjo can actually deliver this EBIT plan after earlier ambitions fell short.
"The company has stated that earlier financial goals for growth, EBITDA margin and cash flow were only partially met, with growth achieved but profitability and cash generation falling short, and if the new SEK 350 million EBIT improvement commitment is not delivered to plan, the share price could adjust downward to reflect weaker than expected earnings and cash flow."
Q3 results keep that concern alive. Net income excluding extra items fell to SEK 58m and EPS declined to SEK 0.213 despite higher sales and EBIT. Working capital days stretched to 88, and SEK 102m of net financial charges, including investment write downs, show that cleaner earnings and cash flows are not yet secured.
The price and this Narrative do not agree. → Uncover what this Narrative says Arjo is actually worth.
Arjo shows how rebuilding margins and repairing balance sheets can affect perceptions of one stock. The real opportunity is identifying businesses that may be undervalued before the market fully connects their financial and strategic progress.
Three companies from the same screener. Open all 191 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com